Translate AMICOR contents if you like

Tuesday, November 03, 2015

Arogya World

Arogya World is a global non-profit working to prevent chronic diseases through education and lifestyle change. Our mission is reflected in our name: "Arogya" in Sanskrit means to live a life without disease.
Arogya World banner
November 2015
Introducing myArogya, our new app for chronic disease prevention for working Indians

myArogya, a new mobile app that helps working Indians prevent chronic disease, is now available on Android and iOS phones. Developed with sole funding from the Cigna Foundation, myArogya includes rich content on awareness and prevention of chronic diseases including diabetes, heart disease, stroke, kidney disease, and complications of diabetes.
Meaning "my Health" in Sanskrit, myArogya is the first-of-its kind chronic disease prevention mobile app designed to help working Indians lead healthier lives. The myArogya App also has food and activity trackers to help people make healthy lifestyle changes. Many other features including a smoking cessation mHealth program, healthy recipe videos, nutritional icons for India, and additional trackers are planned for later phases. 

The myArogya App was developed in partnership with ClickMedix. "We are honored to partner with Arogya World in the development of the first-ever chronic disease prevention mobile application for working Indians," said Ting Shih, Founder and CEO of ClickMedix. "The myArogya app not only has effective health educational messages, but it also has a variety of lifestyle tracking tools to help Indians live healthily."
A formal year-long clinical study in several workplaces is in progress to determine the App's effectiveness in preventing Non-Communicable Diseases (NCDs) like diabetes. The first group of working Indians began to use the App this month, as part of the effectiveness study. "We believe this study can show how a simple, scalable mHealth intervention can help mitigate cardiometabolic risk factors such as increased weight, blood pressure, lipids or glycated haemoglobin among South Asians, who are a 'high-risk' group for NCDs like diabetes and heart diseases," said Dr. Ranjani Harish, myArogya study lead and Arogya World Behaviour Change member who is with the Madras Diabetes Research Foundation (MDRF). The study is in progress at Quinnox, Cyient, Cognizant, and other companies. We are grateful for their ongoing support.  /.../

No comments: